Return Of Buying OTC Drugs With Pre-Tax Accounts Slow To Dawn On Consumers After 10-Year Sunset

"Because of what a lot of consumers are facing right now, layoffs, furloughs, working online, they may not be aware of how this health savings account benefit can serve them at this time,” says Finance Bar CEO Marsha Barnes. CHPA is preparing digital campaign to explain that health savings, flexible spending and similar pre-tax accounts once again can be used for direct purchases of OTC drugs.

CHPA tax free
CHPA says the total health-care value of OTC drugs in the US includes more than consumers' benefiting from access to self-care products.

A decade of lobbying on Capitol Hill succeeded in making OTC drugs again eligible for purchases using pre-tax health savings accounts but more time apparently is needed for the change to resonate with consumers.

The Consumer Healthcare Products Association is preparing a digital campaign to launch later in 2020 to explain that health savings, flexible spending and similar pre-tax accounts once again can be used for direct purchases of OTC drugs

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Legislation

Over The Counter: Brands, Brexit And New Self-Care Business Models, With PAGB’s Michelle Riddalls

 
• By 

HBW Insight catches up with UK OTC industry association CEO Michelle Riddalls to talk about digital self-care and the unrealized promise of Brexit - part 2.

US FDA User Fee Collection Safe In Preliminary Trump 2026 Budget Plan

 
• By 

The preliminary White House 2026 budget plan cuts agency funding, but not so sharply that user fees are excluded from collection.

Plenty For Industry To Do As EU Wastewater Directive Faces Legal Challenges

 
• By 

Engaging with EU member state legislators, stressing the impact of national EPR systems on the accessibility, availability, and affordability of medicines, reformulating products to reduce their financial contribution, and lobbying for expanding the scope of EPR schemes to include other polluting industries are all ways that the European consumer health industry can try and influence the way that the revised Urban Wastewater Treatment Directive is transposed into national legislation, law firm Mason Hayes & Curran explains.

Doctors In The House: Sunscreen Innovation Diagnoses From Health Subcommittee

 

Energy and Commerce Health Subcommittee members, including several health care professionals, make clear their concerns about the US sunscreen market during hearing on reauthorizing FDA’s OMUFA program.

More from Policy & Regulation

Over The Counter: Everything You Wanted To Know About Real World Evidence, With IQVIA’s Volker Spitzer

 
• By 

HBW Insight finds out all about real world evidence and its potential for the OTC industry by chatting with IQVIA Consumer Health's vice president of global research and development and real-world evidence services, Volker Spitzer.

US Tariffs Pose ‘Existential Threat’ To EU Medical Devices Industry

 
• By 

AESGP, MedTech Europe and other associations representing medtech companies including manufacturers of self-care devices call for such products to be included in European Commission proposals for “zero-for-zero” trade in industrial goods between Europe and the US.

Stakeholders Hope US FDA’s Proposed Animal Test Phase-Out For Drugs Will Extend To OTCs, Cosmetics

 
• By 

The US Food and Drug Administration has released a roadmap to adopt new approach methodologies in lieu of animal testing for monoclonal antibody therapies and other drugs, which may include OTC drugs though the proposal does not specifically include cosmetics.